Kann, Michael C. http://orcid.org/0000-0002-5917-0296
Schneider, Emily M.
Almazan, Antonio J. http://orcid.org/0009-0003-4947-3968
Lane, Isabel C.
Bouffard, Amanda A.
Supper, Valentina M. http://orcid.org/0000-0002-3726-1840
Takei, Hana N.
Tepper, Alexander http://orcid.org/0000-0003-1384-9241
Leick, Mark B. http://orcid.org/0000-0003-3111-0221
Larson, Rebecca C. http://orcid.org/0000-0003-0174-061X
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Jan, Max
Article History
Received: 14 July 2023
Revised: 19 November 2023
Accepted: 6 December 2023
First Online: 20 December 2023
Competing interests
: MCK, MVM, and MJ are listed as inventors on patents related to this work and held by the Massachusetts General Hospital and Partners Health Care. BLE has received research funding from Celgene, Deerfield, Novartis, and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Inc., TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics. MVM is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab) and University of Pennsylvania (some licensed to Novartis). MVM holds equity in 2SeventyBio, Century Therapeutics, Genocea, Neximmune, Oncternal, and TCR2 and has served as a consultant for multiple companies involved in cell therapies. MJ has received consulting income from RA Ventures. MJ is an inventor on patents related to molecular switch control of genetically engineered immune effector cell therapies held by Mass General Brigham and the Broad Institute.